id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2007-D-0369-0047,FDA,FDA-2007-D-0369,Attachment 1 - Proposed Product-Specific Bioequivalence Recommendations for Estradiol Transdermal Extended Release Film - (Novartis Pharmaceuticals Corporation - Comment) re FDA-2007-D-0369-0045,Supporting & Related Material,C-Comment (Supporting and Related Material),2010-09-07T04:00:00Z,2010,9,,,2012-11-19T02:18:08Z,,0,0,0900006480ae9e64
FDA-2007-D-0369-0041,FDA,FDA-2007-D-0369,Hyperion Therapeutics - Comment re FDA-2007-D-0369-0040,Supporting & Related Material,C-Comment (Supporting and Related Material),2010-02-03T05:00:00Z,2010,2,,,2010-02-04T00:27:52Z,,0,0,0900006480a8827d
FDA-2007-D-0369-0042,FDA,FDA-2007-D-0369,Hyperion Therapeutics - Letter re FDA-2007-D-0369-0040,Other,LET-Letter,2010-02-03T05:00:00Z,2010,2,2010-02-03T05:00:00Z,,2013-07-27T23:05:46Z,,0,0,0900006480a89680